AVS Bio Expands European Footprint with Acquisition of IPA Europe
Deal News | Aug 06, 2025 | Arlington Capital Partners
Arlington Capital Partners has successfully facilitated the acquisition of ImmunoPrecise Antibodies (Europe) B.V. by its portfolio company, AVS Bio. The acquisition is a strategic effort to boost AVS Bio's capabilities in the bioprocessing and biologics sector, specifically through a European expansion. IPA Europe, obtained from a carve-out of ImmunoPrecise Antibodies Ltd, will bolster AVS Bio with advanced capabilities in antibody discovery and protein expression. Led by Jac Price, AVS Bio aims to integrate IPA Europe as a strategic hub in Europe, further strengthening its reach in the biologics R&D value chain. This move is aligned with Arlington's broader strategy to support healthcare sector advancements through targeted M&A activities. Edgemont Partners acted as the exclusive sell-side advisor in this transaction.
Sectors
- Biotechnology
- Pharmaceuticals
- Private Equity
Geography
- United States – Arlington Capital Partners is based in Washington, D.C., and AVS Bio is headquartered in Norwich, CT.
- Netherlands – IPA Europe is based in Utrecht and Oss, the Netherlands, where it operates its facilities.
Industry
- Biotechnology – The article is centered around the acquisition of a company specializing in antibody discovery and bioprocessing, which are key components of the biotechnology sector.
- Pharmaceuticals – AVS Bio and IPA Europe provide services crucial to pharmaceutical companies, including the development of therapeutics and vaccines.
- Private Equity – Arlington Capital Partners, a private equity firm, is involved in the transaction by facilitating the acquisition through its investment in AVS Bio.
Financials
- $3.8 billion – Size of Arlington Capital Partners' current fund, Fund VI.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Arlington Capital Partners | Private Equity Firm | Company | A private investment firm specializing in government-regulated industries. |
| AVS Bio | Acquiring Company | Company | Portfolio company of Arlington Capital Partners providing bioprocessing services. |
| ImmunoPrecise Antibodies Ltd. | Selling Company | Company | Biotherapeutics company leveraging proprietary technologies for biologics discovery. |
| ImmunoPrecise Antibodies (Europe) B.V. | Target Company | Company | Provides services in antibody discovery and protein production. |
| Edgemont Partners | Sell-side Advisor | Company | Served as exclusive sell-side advisor to ImmunoPrecise Antibodies Ltd. |